Humaid Al-Shamsi, CEO of Burjeel Cancer Institute (BCI) Comprehensive Cancer Center, shared on X:
“From Madrid – The European Oncology Conference – ESMO2026
Among the most important studies from the conference in the presidential session: the DeLLphi-305 study in small cell lung cancer. This type of lung cancer spreads rapidly.
Adding the modern immunotherapy tarlatamab to durvalumab as preventive treatment after initial therapy led to:
A 58% reduction in the risk of death
Survival after one year: 79.4% versus 53.3%
Proceed to the video attached to the post.”
You can also read: DeLLphi-305: Tarlatamab–Durvalumab Redefines First-Line Maintenance in Extensive-Stage SCLC
